These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer. Koehler VF; Adam P; Frank-Raue K; Raue F; Berg E; Hoster E; Allelein S; Schott M; Kroiss M; Spitzweg C Thyroid; 2021 Mar; 31(3):459-469. PubMed ID: 32781914 [No Abstract] [Full Text] [Related]
3. Comparative efficacy and safety of tyrosine kinase inhibitors for thyroid cancer: a systematic review and meta-analysis. Oba T; Chino T; Soma A; Shimizu T; Ono M; Ito T; Kanai T; Maeno K; Ito KI Endocr J; 2020 Dec; 67(12):1215-1226. PubMed ID: 32814730 [TBL] [Abstract][Full Text] [Related]
4. Lenvatinib: Role in thyroid cancer and other solid tumors. Cabanillas ME; Habra MA Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514 [TBL] [Abstract][Full Text] [Related]
5. Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model. Tappenden P; Carroll C; Hamilton J; Kaltenthaler E; Wong R; Wadsley J; Moss L; Balasubramanian S Health Technol Assess; 2019 Feb; 23(8):1-144. PubMed ID: 30821231 [TBL] [Abstract][Full Text] [Related]
6. Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial. Cabanillas ME; de Souza JA; Geyer S; Wirth LJ; Menefee ME; Liu SV; Shah K; Wright J; Shah MH J Clin Oncol; 2017 Oct; 35(29):3315-3321. PubMed ID: 28817373 [TBL] [Abstract][Full Text] [Related]
7. cabozantinib (COMETRIQ⁰). In medullary thyroid cancer: more harmful than beneficial, as is vandetanib. Prescrire Int; 2016 Jan; 25(167):11-3. PubMed ID: 26942253 [TBL] [Abstract][Full Text] [Related]
8. Selective use of vandetanib in the treatment of thyroid cancer. Fallahi P; Di Bari F; Ferrari SM; Spisni R; Materazzi G; Miccoli P; Benvenga S; Antonelli A Drug Des Devel Ther; 2015; 9():3459-70. PubMed ID: 26170630 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of tyrosine kinase inhibitors for advanced metastatic thyroid cancer: A systematic review and network meta-analysis of randomized controlled trials. Zhao M; Li R; Song Z; Miao C; Lu J Medicine (Baltimore); 2024 Apr; 103(15):e37655. PubMed ID: 38608050 [TBL] [Abstract][Full Text] [Related]
11. Pazopanib, Cabozantinib, and Vandetanib in the Treatment of Progressive Medullary Thyroid Cancer with a Special Focus on the Adverse Effects on Hypertension. Milling RV; Grimm D; Krüger M; Grosse J; Kopp S; Bauer J; Infanger M; Wehland M Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30347815 [TBL] [Abstract][Full Text] [Related]
12. The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer. Fallahi P; Ferrari SM; Baldini E; Biricotti M; Ulisse S; Materazzi G; Miccoli P; Antonelli A Expert Rev Anticancer Ther; 2016 Nov; 16(11):1109-1118. PubMed ID: 27650489 [TBL] [Abstract][Full Text] [Related]
13. The evolving field of kinase inhibitors in thyroid cancer. Marotta V; Sciammarella C; Vitale M; Colao A; Faggiano A Crit Rev Oncol Hematol; 2015 Jan; 93(1):60-73. PubMed ID: 25240824 [TBL] [Abstract][Full Text] [Related]
14. Vandetanib for the treatment of medullary thyroid cancer. Chau NG; Haddad RI Clin Cancer Res; 2013 Feb; 19(3):524-9. PubMed ID: 23231950 [TBL] [Abstract][Full Text] [Related]
15. Sorafenib for the treatment of thyroid cancer: an updated review. Krajewska J; Handkiewicz-Junak D; Jarzab B Expert Opin Pharmacother; 2015 Mar; 16(4):573-83. PubMed ID: 25605317 [TBL] [Abstract][Full Text] [Related]